glp-1 agonists and anesthesia 🇬🇧 Perioperative Management of New Popular Agents: (GLP-1 RA: semaglutide, tirzepatide) These drugs delay gastric emptying → patients may have a “full stomach” despite fasting This increases risk of regurgitation ASA Advises No Longer Holding

These findings underscore the potential for GLP-1 RAs to offer tailored protection against complex diabetic complications, marking an advancement in personalized medicine for managing diabetes-acute kidney disease.

Thirteen trials involving 5,807 participants were identified

In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making ...

Just steady, 8-hour support that works quietly while you live your life

The glp-1 agonists market is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026 to 2032.

Designed in an easy-to-use tablet format, this product provides a convenient alternative to injectable GLP-1 options